NeuroSense Therapeutics Warrant
NRSNW
2 hedge funds and large institutions have $24.6K invested in NeuroSense Therapeutics Warrant in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0.28% less ownership
Funds ownership: 0.28% → 0% (-0.28%)
40% less capital invested
Capital invested by funds: $41.3K → $24.6K (-$16.7K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$114 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $24.2K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $397 | -$114 | -190 | -13% |
|
NRSNW Hedge Fund Activity: Q3 2025 in Review
2 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q3 2025, worth a combined $24.6K — down 40% from $41.3K a quarter earlier.
Fund positioning in NRSNW was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $114.
- 2 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $24.6K of NeuroSense Therapeutics Warrant stock for Q3 2025, down 40% quarter-over-quarter.
- 0 funds opened new NeuroSense Therapeutics Warrant positions in Q3 2025 and 0 closed out.
- The largest NeuroSense Therapeutics Warrant seller in Q3 2025 was UBS Group, an estimated $114 sold.
Based on aggregated 13F filings for Q3 2025.